Skip to main content
. 2021 May 4;11:663406. doi: 10.3389/fonc.2021.663406

Figure 3.

Figure 3

Expression of ICs in BM-derived T cells. (A) PCA of CD4+ or CD8+ T cells from AML patients and controls. (B) Gene expression patterns of ICs in CD4+ T cells from leukemia patients compared to controls (30 ligands and 30 receptors). Dot plots indicate the gene expression profiles (red arrows showing upregulated ICs and blue arrows indicating downregulated ICs; Fold difference ≥ 1.3). Heatmaps illustrated the gene expression patterns in respective AML risk groups. (C) GSEA representing the normalized enrichment score (NES) of IC gene sets on CD4+ T cells (AML vs. ctrl). (D) Gene expression patterns of ICs in CD8+ T cells from leukemia patients compared to controls. Dot plots show the gene expression profiles and heatmaps illustrate the expression patterns in respective AML risk groups. (E) GSEA representing the NES of IC gene sets on CD8+ T cells (AML vs. ctrl). (F) Kaplan–Meier plots of overall survival (OS) for AML patients in the study cohort according to the gene expression signature of activating or inhibitory ICs in CD8+ T cells. Statistics: student’s t-test and log-rank test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns, not significant.